Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 39kWORD 17k
27 February 2019
E-001049-19
Question for written answer E-001049-19
to the Commission
Rule 130
Maria Grapini (S&D)

 Subject:  Access to essential medicines for all EU citizens
 Answer in writing 

Although there is a single market in the European Union, many types of essential medicines (cancer treatments, etc.) are not found in all Member States, which has an adverse impact on the health of patients there.

Manufacturers very often channel their sales to those markets where prices are higher. There should be equal access to essential treatments and medicines for all EU citizens and patients, regardless of Member States’ economic considerations.

How will the Commission put a stop to practices that allow some pharmaceutical companies to charge excessive prices for certain essential medicines, bearing in mind the need for European solidarity and for all patients in all EU countries to have access to essential treatments and medicines?

Original language of question: RO 
Last updated: 11 March 2019Legal notice